Trials / Recruiting
RecruitingNCT07008118
A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
A Phase 1, Open-Label, Multicenter Study of INCA035784 in Participants With Myeloproliferative Neoplasms
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is being conducted to evaluate the safety and tolerability of INCA035784 in participants with myeloproliferative neoplasms.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | INCA035784 | INCA035784 will be administered at the assigned dose in the dose escalation part and at the protocol defined dose in the dose expansion part. |
Timeline
- Start date
- 2025-10-01
- Primary completion
- 2028-03-14
- Completion
- 2029-12-14
- First posted
- 2025-06-06
- Last updated
- 2026-04-06
Locations
26 sites across 5 countries: United States, Australia, Belgium, Germany, Italy
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07008118. Inclusion in this directory is not an endorsement.